<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nitrates in the management of chronic coronary syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nitrates in the management of chronic coronary syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nitrates in the management of chronic coronary syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph P Kannam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">Nitroglycerin</a> was the first medication used in 1879 by William Murrell for the treatment of angina pectoris [<a href="#rid1">1</a>] and, in its extended release forms, still remains first-line drug therapy for many patients [<a href="#rid2">2,3</a>]. </p><p>While they act as venodilators, coronary vasodilators, and modest arteriolar dilators, the primary antiischemic effect of nitrates is to decrease myocardial oxygen demand by producing systemic vasodilation more than coronary vasodilation. This systemic vasodilation reduces left ventricular systolic wall stress.</p><p>In patients with exertional stable angina, nitrates improve exercise tolerance, time to onset of angina, and ST-segment depression during exercise testing. In combination with beta blockers or calcium channel blockers, nitrates produce greater antianginal and antiischemic effects. (See  <a class="medical medical_review" href="/d/html/1472.html" rel="external">"Approach to the patient with suspected angina pectoris"</a> and  <a class="medical medical_review" href="/d/html/1483.html" rel="external">"Chronic coronary syndrome: Overview of care"</a>.)</p><p>Its use, however, is complicated by the development of tolerance with continuous therapy. (See <a class="local">'Nitrate tolerance'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Nitrates dilate veins, arteries, and coronary arteries by relaxing vascular smooth muscle [<a href="#rid4">4</a>]. They produce these effects by entering vascular smooth muscle cells where they are metabolized to 1,2-glyceryl dinitrate and nitrite, via mitochondrial aldehyde dehydrogenase-2 (ALDH2 or mtALDH), and then nitric oxide and S-nitrosothiols  (<a class="graphic graphic_figure graphicRef50622" href="/d/graphic/50622.html" rel="external">figure 1</a>) [<a href="#rid5">5</a>]. Sulfhydryl groups on ALDH2 are required for activity, which can explain the known sulfhydryl requirement for vascular smooth muscle relaxation by nitrates [<a href="#rid5">5</a>].</p><p>Most of the antiischemic efficacy of nitrates pertains to their ability to decrease myocardial oxygen demand as a result of systemic vasodilatation rather than any activity as a coronary vasodilator. Nitrates do not have a direct effect on cardiac chronotropy or inotropy.</p><p class="headingAnchor" id="H3"><span class="h2">Effect on systemic hemodynamics</span><span class="headingEndMark"> — </span>The nitrates are primarily venodilators due to increased bioavailability to venous smooth muscle cells. Venodilation lowers preload (left ventricular end-diastolic pressure) and therefore reduces wall stress, resulting in a decrease in myocardial oxygen demand. The fall in preload is more pronounced with sitting or standing.</p><p>At low doses, nitrates cause a lesser degree of arterial and arteriolar dilatation, leading to little or no change in systemic vascular resistance or blood pressure [<a href="#rid4">4</a>]. As the dose is increased, the blood pressure falls, often accompanied by reflex tachycardia. Wall stress is reduced at the lower blood pressure, resulting in a further decrease in myocardial oxygen demand.</p><p>Some patients, especially those with hypovolemia, are extremely sensitive to the arteriolar effect of nitrates and develop a profound drop in blood pressure which can aggravate myocardial ischemia. In addition, arteriolar dilatation of the face can cause flushing and meningeal arterial dilatation can cause headache, two common side effects of these drugs.</p><p>Problems can also occur with excessive venodilation. This can result in a marked decrease in venous return, which induces cardiac emptying that triggers mechanical receptors in the heart, possibly leading to hypotension and bradycardia consistent with the Bezold-Jarisch reflex (vasovagal response) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/1050.html" rel="external">"Reflex syncope in adults and adolescents: Clinical presentation and diagnostic evaluation"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Effect on coronary hemodynamics</span><span class="headingEndMark"> — </span>A nitrate-induced increase in coronary blood flow has been proposed as a potential mechanism for relieving ischemia. Animal and human studies have shown that nitrates dilate both normal and abnormal coronary arteries [<a href="#rid7">7</a>]; this response is preserved in saphenous vein grafts [<a href="#rid8">8</a>]. The clinical importance of this effect is uncertain because the coronary arterioles in patients with a flow-limiting coronary stenosis are already dilated to maintain resting blood flow, making further coronary dilation during ischemia difficult.</p><p>There are, however, settings in which a direct effect on coronary hemodynamics may be beneficial. Nitrates can reduce or reverse coronary vasospasm [<a href="#rid9">9</a>]. Thus, patients with primarily vasospastic angina or a large vasoconstrictor component to their angina can benefit from the direct coronary action of nitrate therapy. Nitrates also indirectly improve subendocardial blood flow as the reduction in left ventricular end-diastolic pressure induced by systemic venous dilatation decreases the resistance to coronary blood flow from epicardium to endocardium [<a href="#rid10">10</a>]. In addition, nitrates may lower the resistance to collateral vessel blood flow [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Antiplatelet and antithrombotic properties</span><span class="headingEndMark"> — </span>Nitrates have significant antiplatelet and antithrombotic properties; however the clinical importance of these potentially beneficial effects is unclear [<a href="#rid12">12</a>]. Stimulation of platelet guanylate cyclase by nitrates prevents fibrinogen binding to platelet IIb/IIIa receptors, which is essential for platelet aggregation [<a href="#rid13">13</a>]. Transdermal <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> has been shown to inhibit platelet aggregation and thrombus formation in patients with angina [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H3981012660"><span class="h1">USE</span><span class="headingEndMark"> — </span>Nitrates, usually in the form of a sublingual preparation, are the first-line therapy for the treatment of <strong>acute</strong> anginal symptoms. Patients should be instructed to use them at the onset of angina. </p><p>A sublingual <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> tablet may be recommended for the prophylaxis of anginal episodes and we often recommend them in patients with predictable and stable angina. For example, patients who have undergone incomplete revascularization who get angina at a predictable workload may be good candidates for prophylactic nitroglycerin. Some patients may benefit from a repeat dose if angina occurs during the activity.</p><p>Long-acting nitrates are added to beta blockers (with or without calcium channel blockers) to control stable angina. In patients with exertional stable angina, chronic nitrate therapy using oral or dermal preparations improves exercise tolerance, time to onset of angina, and ST-segment depression during exercise testing. In combination with beta blockers or calcium channel blockers, nitrates produce greater antianginal and antiischemic effects compared with those drugs without nitrates. However, the long-term utility of nitrates is limited by the induction of nitrate tolerance.</p><p class="headingAnchor" id="H6"><span class="h1">NITRATE TOLERANCE</span><span class="headingEndMark"> — </span>Tolerance has been a major problem with the use of nitrates as chronic antianginal therapy. It was first observed in individuals exposed to <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> during the production of explosives. These workers developed severe headache and dizziness after the initial exposure. These side effects would then diminish after several days. If, however, exposure was avoided for several days, the symptoms would return after reexposure.</p><p>A similar sequence occurs in humans as chronic nitrate therapy for angina pectoris is associated with attenuation and at times abolition of the hemodynamic and antianginal effects.</p><p class="headingAnchor" id="H7"><span class="h2">Mechanisms of tolerance</span><span class="headingEndMark"> — </span>How nitrate tolerance occurs is incompletely understood. It is due to attenuation of the vascular effect of nitrates, not to altered pharmacokinetics [<a href="#rid2">2</a>].</p><p>At least three, not mutually exclusive, mechanisms have been proposed to explain the development of nitrate tolerance [<a href="#rid2">2</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> bioconversion to 1,2-glyceryl dinitrate with decreased formation of nitric oxide. This effect is nitrate-specific and is not seen with non-nitrate sources of nitric oxide such as <a class="drug drug_general" data-topicid="9707" href="/d/drug information/9707.html" rel="external">nitroprusside</a> [<a href="#rid15">15</a>]. Consistent with this theory are the experimental observations that there is no tolerance to the effect of S-nitrosothiols and that the activity of mitochondrial aldehyde dehydrogenase-2 (mtALDH), the enzyme required for metabolism of nitrates to 1,2-glyceryl dinitrate in markedly reduced [<a href="#rid5">5</a>]. The same findings can be induced by inhibitors of mtALDH [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced bioactivity of nitric oxide [<a href="#rid16">16</a>]. Consistent with this theory is the finding in an animal study that vascular and hemodynamic tolerance to nitrates occurred despite high levels of nitric oxide and rates of nitric oxide formation that were similar in those animals that were not tolerant [<a href="#rid17">17</a>]. Also in support of this hypothesis is that transgenic animals that overexpress endothelial nitric oxide synthase have chronically elevated nitric oxide release, which is associated with reduced vascular reactivity to nitric oxide-mediated vasodilators [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activation of the vasoconstrictor renin-angiotensin-aldosterone and sympathetic nervous systems in response to nitrate-induced vasodilation [<a href="#rid19">19,20</a>]. There is also increased peripheral sensitivity to these vasoconstrictors, an effect that can be reversed by angiotensin converting enzyme inhibition [<a href="#rid19">19</a>]. Abnormal coronary vasoconstrictor responses have also been described with continuous nitrate exposure [<a href="#rid21">21</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>Several strategies have been attempted to prevent nitrate tolerance, the most effective being intermittent therapy with an adequate nitrate-free interval (around 8 to 10 hours). It is thought that a nitrate-free interval permits the regeneration of reduced sulfhydryl groups, thereby restoring vascular responsiveness to nitrates. Chronic therapy with <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a>, a sulfhydryl donor, does not appear to be effective in patients with stable angina [<a href="#rid22">22</a>], in contrast to its acute benefit with intravenous <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> in those with unstable angina. (See  <a class="medical medical_review" href="/d/html/64.html" rel="external">"Nitrates in the management of acute coronary syndrome"</a>.)</p><p>There are, however, two concerns regarding intermittent therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>A time-zero effect, which refers to a deterioration in exercise performance relative to placebo prior to the morning dose of nitrates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rebound angina, which refers to an increase in angina during the nitrate-free interval. There may result from a supersensitivity of the vessel wall to vasoconstrictors [<a href="#rid23">23</a>] or an increased vasomotor response to acetylcholine, suggesting the development of endothelial dysfunction [<a href="#rid24">24</a>].</p><p></p><p>Whether these effects occur to a clinically significant degree remains unclear [<a href="#rid25">25-28</a>]. Their importance with the different nitrate preparations will be discussed below.</p><p>Several other methods have been proposed to reduce nitrate tolerance, although <strong>none</strong> is as yet used clinically:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">Folic acid</a> can reverse endothelial dysfunction, possibly by restoring the bioavailability of tetrahydrobiopterin, a cofactor for nitric oxide synthase and/or <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a>, its substrate. This suggests a possible role for folic acid in preventing nitrate tolerance. This was examined in a study of 18 subjects who were randomly assigned to folic acid (10 mg/day) or placebo for one week; all patients received continuous transdermal <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> (0.6 mg/hour) [<a href="#rid29">29</a>]. Compared to placebo, folic acid prevented the development of both endothelial dysfunction and nitrate tolerance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment for five to 10 days with L-arginine, the substrate for nitric oxide synthesis, can modify or prevent the development of nitrate tolerance during continuous transdermal <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> use [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">Hydralazine</a> may attenuate nitrate tolerance, perhaps by preventing superoxide generation [<a href="#rid31">31</a>]. This relationship could contribute to the efficacy of combined nitrate-hydralazine therapy in patients with heart failure. (See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.) In patients with angina pectoris, hydralazine should be given in combination with a beta blocker because of the reflex sympathetic activation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other antioxidants may be helpful, at least from a theoretical perspective, such as <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> [<a href="#rid32">32</a>] and <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> [<a href="#rid33">33,34</a>]. In addition, <a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">carvedilol</a>, a beta and alpha blocker that also has antioxidant activity, may prevent nitrate tolerance [<a href="#rid35">35</a>]. The importance of antioxidant activity was suggested by a second report which compared carvedilol with another beta and alpha blocker (arotinolol) that was devoid of antioxidant properties; only carvedilol prevented nitrate tolerance [<a href="#rid36">36</a>].</p><p></p><p>Other drugs have had variable or no effect. These include angiotensin converting enzyme inhibitors [<a href="#rid19">19,37-39</a>], and diuretics, which may have some antianginal activity by reducing the plasma volume [<a href="#rid39">39,40</a>].</p><p class="headingAnchor" id="H9"><span class="h1">COMMONLY USED NITRATE PREPARATIONS</span><span class="headingEndMark"> — </span>Numerous nitrate preparations are commercially available, including sublingual, buccal, oral, spray, ointment, and transdermal preparations.</p><p class="headingAnchor" id="H10"><span class="h2">Sublingual nitroglycerin</span><span class="headingEndMark"> — </span>Sublingual <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> remains the therapy of choice for acute anginal episodes and prophylactically for activities known to elicit angina such as mowing the lawn, playing tennis, or walking in cold weather. Our impression is that the prophylactic use of nitroglycerin is not sufficiently emphasized to patients.</p><p>The onset of action is within two to five minutes and the duration of action is 15 to 30 minutes. Tolerance is not a problem with sublingual <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> because of its intermittent administration, even in patients on chronic nitrate therapy [<a href="#rid41">41</a>].</p><p>The recommended <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> dose is 0.3 mg (1/200 grains) to 0.4 mg (1/150 grains). </p><p>The traditional recommendation is for patients to take one <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> dose sublingually every five minutes for up to three doses before calling for emergency medical services (EMS) evaluation. However, studies suggest that this approach may result in significant delays in obtaining EMS assistance [<a href="#rid42">42,43</a>]. For patients known to their providers to have frequent angina, physicians may consider a selected, more tailored message that takes into account the frequency and character of the patient's angina and their typical time course of response to nitroglycerin.</p><p>If the sublingual <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> is potent, a slight tingling sensation should be felt under the tongue. Tablets that crumble easily should not be used. The sublingual mucosa should be moist for adequate dissolution and absorption of the tablet. A drink of water in patients with dry sublingual mucosa prior to ingestion of the tablet may be necessary [<a href="#rid44">44</a>].</p><p><a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">Nitroglycerin</a> tablets are both heat and light sensitive. They should therefore be stored in a tightly capped dark bottle in the refrigerator with only a small supply being carried by the patient. Nitroglycerin tablets in an opened bottle should be discarded after 12 months. </p><p>Patient education is extremely important for the proper use of sublingual <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a>. A survey of 50 patients revealed a surprising lack of knowledge concerning the administration, storage, and side effects of this preparation [<a href="#rid45">45</a>]. Only 12 percent knew the maximum dose in a 15 minute period, 28 percent knew the proper storage conditions for sublingual tablets, and 52 percent knew the most common side effects. It is important for health care providers, when reviewing the medication list of coronary artery disease patients, to ensure that patients have an active prescription for nitroglycerin.</p><p class="headingAnchor" id="H11"><span class="h2">Nitroglycerin spray</span><span class="headingEndMark"> — </span>A less popular but equally effective means of administering sublingual <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> is by metered dose spray. The spray dispenses of 0.4 mg of nitroglycerin. One to two sprays can be used at the start of an attack and up to three sprays can be used in a 15 minute period. It has a shelf life of two to three years [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Isosorbide dinitrate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">Isosorbide dinitrate</a> (ISDN) is uncommonly used in practice. It has an onset of action within 15 to 30 minutes and the duration of action is three to six hours. Low bioavailability from hepatic metabolism has necessitated relatively large doses of 10 to 40 mg three times daily.</p><p>The beneficial effects of a single dose of ISDN (15, 30, 60, 120 mg) were demonstrated in 12 patients with chronic stable angina [<a href="#rid41">41</a>]. There was a dose-related reduction in systolic blood pressure that persisted for eight hours. Exercise duration improved up to eight hours after the 15 and 30 mg dose; there was no added benefit with the 60 and 120 mg doses  (<a class="graphic graphic_figure graphicRef61032" href="/d/graphic/61032.html" rel="external">figure 2</a>).</p><p>Unfortunately, tolerance has limited the usefulness of ISDN as a chronic antianginal agent. In the study above, ISDN was given four times daily for two weeks [<a href="#rid47">47</a>]: both the blood pressure and exercise responses were attenuated  (<a class="graphic graphic_figure graphicRef61032" href="/d/graphic/61032.html" rel="external">figure 2</a>). In particular, exercise duration was only increased for two hours after a dose and doses above 15 mg four times daily produced no added benefit. The development of tolerance occurred despite higher plasma concentrations of ISDN during maintenance therapy.</p><p>Several studies have altered the drug regimen in an attempt to prevent the development of tolerance. One study, for example, examined the effect of 30 mg of ISDN given two (7 AM and 12 PM), three (7 AM, 12 PM, and 5 PM), and four (7 AM, 12 PM, 5 PM, and 11 PM) times daily for one week [<a href="#rid48">48</a>]. Exercise duration until the onset of angina was assessed before and one, three, and five hours after the morning dose. After a single initial dose, exercise duration significantly increased versus placebo over the five hour observation period. After one week of therapy, two and three (but not four) times daily dosing was associated with improved exercise tolerance compared placebo; however, the benefit was less pronounced late in the day, indicating partial tolerance. One limitation to the clinical utility of these results is that the response was measured only to the morning dose of ISDN.</p><p>Another report questioned the antianginal efficacy of three times daily ISDN [<a href="#rid49">49</a>]. Eight patients with chronic stable angina were given ISDN at 8 AM, 1 PM, and 6 PM. Exercise time increased for at most three hours after the morning and afternoon dose but not substantially after the evening dose  (<a class="graphic graphic_figure graphicRef79122" href="/d/graphic/79122.html" rel="external">figure 3</a>). It was concluded that ISDN given three times daily offered antianginal protection for at most six hours.</p><p class="headingAnchor" id="H520925516"><span class="h2">Isosorbide mononitrate</span><span class="headingEndMark"> — </span>Extended-release <a class="drug drug_general" data-topicid="8581" href="/d/drug information/8581.html" rel="external">isosorbide mononitrate</a> is the most commonly used oral nitrate. The dose and side effects of the mononitrates are similar to those of <a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">isosorbide dinitrate</a>, and intolerance can occur [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Transdermal nitroglycerin</span><span class="headingEndMark"> — </span>Transdermal <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> patches obtained United States Food and Drug Administration approval in 1981 and gained wide acceptance for its convenience. They are rarely used by our contributors.</p><p class="headingAnchor" id="H26779294"><span class="h2">Pentaerithrityl tetranitrate</span><span class="headingEndMark"> — </span>Pentaerithrityl tetranitrate is a long-acting nitrate vasodilator that has been used in patients with angina, in part because some studies have shown that it did not induce nitrate tolerance [<a href="#rid51">51</a>]. In the CLEOPATRA study, 655 patients with chronic stable angina were randomly assigned to pentaerithrityl tetranitrate (80 mg twice) daily or placebo [<a href="#rid52">52</a>]. After 12 weeks, there was no difference in the primary end point of total exercise duration.</p><p class="headingAnchor" id="H14"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Headache and flushing are common symptoms in patients taking nitrate therapy, and hypotension can occur. </p><p class="headingAnchor" id="H15"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Nitrates are contraindicated in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have taken <a class="drug drug_general" data-topicid="9643" href="/d/drug information/9643.html" rel="external">sildenafil</a> or <a class="drug drug_general" data-topicid="10172" href="/d/drug information/10172.html" rel="external">vardenafil</a> within 24 hours or <a class="drug drug_general" data-topicid="10108" href="/d/drug information/10108.html" rel="external">tadalafil</a> within 48 hours (because of the risk of severe hypotension). (See  <a class="medical medical_review" href="/d/html/1541.html" rel="external">"Sexual activity in patients with cardiovascular disease"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with hypertrophic cardiomyopathy in whom nitrates can induce or increase outflow tract obstruction, even in those not known to have a resting gradient. (See  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction", section on 'Therapies to avoid'</a> and  <a class="medical medical_review" href="/d/html/4950.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction", section on 'Chest discomfort'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with suspected right ventricular infarction, nitrates should be avoided, if possible, because of the increased risk of inducing hypotension. (See  <a class="medical medical_review" href="/d/html/75.html" rel="external">"Right ventricular myocardial infarction"</a>.)</p><p></p><p>In addition, nitrates should be used cautiously in patients with severe aortic stenosis or volume depletion.</p><p>Our recommendations for the use of nitrates are generally consistent with those of guideline organizations.</p><p class="headingAnchor" id="H2234114228"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115939.html" rel="external">"Society guideline links: Chronic coronary syndrome"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nitrates</strong> – Sublingual <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> remains the treatment of choice for an acute anginal attack or for prophylaxis prior to activities known to exacerbate angina. Chronic nitrate therapy is used to prevent recurrent anginal episodes but must be dosed correctly in order to prevent tolerance. Allowing for a sufficient nitrate-free interval, nitrates may be given during the day or at night depending upon the patient's symptom complex:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with primarily exertional angina, nitrates are given during the day when the patient is more active.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with nocturnal angina or heart failure, therapy at night may be more beneficial.</p><p></p><p class="bulletIndent1">Nitrates are especially useful in patients with heart failure, particularly at night in those with significant orthopnea or paroxysmal nocturnal dyspnea. In addition, patients with exertional dyspnea may benefit if nitrates are taken prior to exertion.</p><p></p><p class="bulletIndent1">There is no difference in efficacy among <a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">isosorbide dinitrate</a> and transdermal <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a>. Because of the problems with tolerance and rebound angina in the nitrate-free interval, we usually reserve chronic nitrate therapy for second line antianginal therapy. What follows are our recommendations for administering the most commonly used nitrate preparations. The use of nitrates in specific clinical settings is discussed separately. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sublingual </strong><a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> – Sublingual nitroglycerin remains the therapy of choice for acute anginal episodes and prophylactically for activities known to elicit angina such as mowing the lawn, playing tennis, or walking in cold weather. Our impression is that the prophylactic use of nitroglycerin is not sufficiently emphasized to patients.</p><p></p><p class="bulletIndent2">We give all patients with stable angina a prescription for sublingual <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> (tablets or spray, depending upon patient preference). Patient education concerning proper dosing, storage, and side effects of sublingual nitroglycerin is extremely important. (See <a class="local">'Sublingual nitroglycerin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">Isosorbide dinitrate</a> –<strong> </strong>Proper dosing with isosorbide dinitrate is essential to prevent tolerance. We recommend a dosing schedule of 8 AM, 1 PM, and 6 PM, which results in a 14 hour nitrate dose-free interval. We begin with a dose of 10 mg three times daily, and advance to 40 mg three times daily as needed. Alternatively, isosorbide dinitrate can be taken twice daily at 8 AM and 4 PM. For this reason, we rarely use this preparation; we prefer the sustained-release once-a-day preparation (see below) since it can be given once daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8581" href="/d/drug information/8581.html" rel="external">Isosorbide mononitrate</a> – Some of our experts prefer isosorbide mononitrate to dinitrate. When chosen, we prefer the sustained release preparation given its ease of use. (See <a class="local">'Isosorbide mononitrate'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transdermal </strong><a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> – Nitroglycerin can be given transdermally in the form of a patch. The patient must remember to remove the patch for 12 to 14 hours. If the patient has angina with activity, we suggest that the patch be applied at 8 AM and removed at 8 PM. If the patient has significant nocturnal angina, the patch can be worn from 8 PM to 8 AM. We begin with a dose of 0.2 mg/hour; the dose can be increased to 0.8 mg/hour as needed. Since it can be difficult to remember to remove the patch after 12 hours, we do not use this option often, preferring the once-daily sustained-release <a class="drug drug_general" data-topicid="8581" href="/d/drug information/8581.html" rel="external">isosorbide mononitrate</a>.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Murrell W. Nitro-glycerine as a remedy for angina pectoris. Lancet 1879; 1:80.</a></li><li><a class="nounderline abstract_t">Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 1998; 338:520.</a></li><li class="breakAll">Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).</li><li><a class="nounderline abstract_t">Abrams J. Hemodynamic effects of nitroglycerin and long-acting nitrates. Am Heart J 1985; 110:216.</a></li><li><a class="nounderline abstract_t">Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 2002; 99:8306.</a></li><li><a class="nounderline abstract_t">Aerts A, Dendale P, Strobel G, Block P. Sublingual nitrates during head-up tilt testing for the diagnosis of vasovagal syncope. Am Heart J 1997; 133:504.</a></li><li><a class="nounderline abstract_t">Brown BG, Bolson E, Petersen RB, et al. The mechanisms of nitroglycerin action: stenosis vasodilatation as a major component of the drug response. Circulation 1981; 64:1089.</a></li><li><a class="nounderline abstract_t">Berglund H, Luo H, Nishioka T, et al. Preserved vasodilatory response to nitroglycerin in saphenous vein bypass grafts. Circulation 1996; 94:2871.</a></li><li><a class="nounderline abstract_t">Ginsburg R, Lamb IH, Schroeder JS, et al. Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm. Am Heart J 1982; 103:44.</a></li><li><a class="nounderline abstract_t">Bache RJ, Ball RM, Cobb FR, et al. Effects of nitroglycerin on transmural myocardial blood flow in the unanesthetized dog. J Clin Invest 1975; 55:1219.</a></li><li><a class="nounderline abstract_t">Cohen MV, Downey JM, Sonnenblick EH, Kirk ES. The effects of nitroglycerin on coronary collaterals and myocardial contractility. J Clin Invest 1973; 52:2836.</a></li><li><a class="nounderline abstract_t">Knight CJ, Panesar M, Wilson DJ, et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997; 95:125.</a></li><li><a class="nounderline abstract_t">Loscalzo J. Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol 1992; 70:18B.</a></li><li><a class="nounderline abstract_t">Lacoste LL, Théroux P, Lidón RM, et al. Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris. Am J Cardiol 1994; 73:1058.</a></li><li><a class="nounderline abstract_t">Sage PR, de la Lande IS, Stafford I, et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation 2000; 102:2810.</a></li><li><a class="nounderline abstract_t">Mangione NJ, Glasser SP. Phenomenon of nitrate tolerance. Am Heart J 1994; 128:137.</a></li><li><a class="nounderline abstract_t">Laursen JB, Mülsch A, Boesgaard S, et al. In vivo nitrate tolerance is not associated with reduced bioconversion of nitroglycerin to nitric oxide. Circulation 1996; 94:2241.</a></li><li><a class="nounderline abstract_t">Ohashi Y, Kawashima S, Hirata Ki, et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 1998; 102:2061.</a></li><li><a class="nounderline abstract_t">Heitzer T, Just H, Brockhoff C, et al. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol 1998; 31:83.</a></li><li><a class="nounderline abstract_t">Parker JO, Parker JD. Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance. Am J Cardiol 1992; 70:93B.</a></li><li><a class="nounderline abstract_t">Caramori PR, Adelman AG, Azevedo ER, et al. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol 1998; 32:1969.</a></li><li><a class="nounderline abstract_t">Münzel T, Holtz J, Mülsch A, et al. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation 1989; 79:188.</a></li><li><a class="nounderline abstract_t">Hébert D, Lam JY. Nitroglycerin rebound associated with vascular, rather than platelet, hypersensitivity. J Am Coll Cardiol 2000; 36:2311.</a></li><li><a class="nounderline abstract_t">Azevedo ER, Schofield AM, Kelly S, Parker JD. Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol 2001; 37:505.</a></li><li><a class="nounderline abstract_t">Freedman SB, Daxini BV, Noyce D, Kelly DT. Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: potential role of rebound ischemia during the nitrate-free period. J Am Coll Cardiol 1995; 25:349.</a></li><li><a class="nounderline abstract_t">Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval. Circulation 1995; 91:973.</a></li><li><a class="nounderline abstract_t">Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group. Circulation 1995; 91:1368.</a></li><li><a class="nounderline abstract_t">Thadani U, Maranda CR, Amsterdam E, et al. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med 1994; 120:353.</a></li><li><a class="nounderline abstract_t">Gori T, Burstein JM, Ahmed S, et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001; 104:1119.</a></li><li><a class="nounderline abstract_t">Parker JO, Parker JD, Caldwell RW, et al. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J Am Coll Cardiol 2002; 39:1199.</a></li><li><a class="nounderline abstract_t">Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995; 26:1575.</a></li><li><a class="nounderline abstract_t">Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation 1997; 96:2545.</a></li><li><a class="nounderline abstract_t">Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of the preventive effect of supplemental oral vitamin C on attenuation of development of nitrate tolerance. J Am Coll Cardiol 1998; 31:1323.</a></li><li><a class="nounderline abstract_t">Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of ascorbate on the preventive effect of nitrate tolerance in patients with congestive heart failure. Circulation 1998; 97:886.</a></li><li><a class="nounderline abstract_t">Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. J Am Coll Cardiol 1998; 32:1194.</a></li><li><a class="nounderline abstract_t">Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. J Am Coll Cardiol 1998; 32:1201.</a></li><li><a class="nounderline abstract_t">Katz RJ, Levy WS, Buff L, Wasserman AG. Prevention of nitrate tolerance with angiotension converting enzyme inhibitors. Circulation 1991; 83:1271.</a></li><li><a class="nounderline abstract_t">Dakak N, Makhoul N, Flugelman MY, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990; 66:608.</a></li><li><a class="nounderline abstract_t">Cotter G, Metzkor-Cotter E, Kaluski E, et al. Usefulness of losartan, captopril, and furosemide in preventing nitrate tolerance and improving control of unstable angina pectoris. Am J Cardiol 1998; 82:1024.</a></li><li><a class="nounderline abstract_t">Parker JD, Parker AB, Farrell B, Parker JO. Effects of diuretic therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina. Circulation 1996; 93:691.</a></li><li><a class="nounderline abstract_t">Lee G, Mason DT, De Maria AN. Effects of long-term oral administration of isosorbide dinitrate on the antianginal response to nitroglycerin. Absence of nitrate cross-tolerance and self-tolerance shown by exercise testing. Am J Cardiol 1978; 41:82.</a></li><li><a class="nounderline abstract_t">Leslie WS, Urie A, Hooper J, Morrison CE. Delay in calling for help during myocardial infarction: reasons for the delay and subsequent pattern of accessing care. Heart 2000; 84:137.</a></li><li><a class="nounderline abstract_t">Simon AB, Feinleib M, Thompson HK Jr. Components of delay in the pre-hospital phase of acute myocardial infarction. Am J Cardiol 1972; 30:476.</a></li><li><a class="nounderline abstract_t">Rasler FE. Ineffectiveness of sublingual nitroglycerin in patients with dry mucous membranes. N Engl J Med 1986; 314:181.</a></li><li><a class="nounderline abstract_t">Bailie GR, Kay EA. Patients' knowledge of sublingual glyceryl trinitrate. BMJ 1988; 297:32.</a></li><li><a class="nounderline abstract_t">NitroMist nitroglycerin spray for angina. Med Lett Drugs Ther 2011; 53:23.</a></li><li><a class="nounderline abstract_t">Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy. Am J Cardiol 1982; 49:411.</a></li><li><a class="nounderline abstract_t">Parker JO, Farrell B, Lahey KA, Moe G. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987; 316:1440.</a></li><li><a class="nounderline abstract_t">Bassan MM. The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate. J Am Coll Cardiol 1990; 16:936.</a></li><li><a class="nounderline abstract_t">Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993; 72:1249.</a></li><li><a class="nounderline abstract_t">Münzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 2011; 123:2132.</a></li><li><a class="nounderline abstract_t">Münzel T, Meinertz T, Tebbe U, et al. Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: a 12-week, randomized, double-blind, placebo-controlled trial. Eur Heart J 2014; 35:895.</a></li></ol></div><div id="topicVersionRevision">Topic 1549 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nitro-glycerine as a remedy for angina pectoris</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9468470" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nitrate therapy for stable angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9468470" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nitrate therapy for stable angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3925741" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hemodynamic effects of nitroglycerin and long-acting nitrates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12048254" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Identification of the enzymatic mechanism of nitroglycerin bioactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141371" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sublingual nitrates during head-up tilt testing for the diagnosis of vasovagal syncope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6794931" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The mechanisms of nitroglycerin action: stenosis vasodilatation as a major component of the drug response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8941115" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Preserved vasodilatory response to nitroglycerin in saphenous vein bypass grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7034513" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/805796" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effects of nitroglycerin on transmural myocardial blood flow in the unanesthetized dog.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4201267" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effects of nitroglycerin on coronary collaterals and myocardial contractility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8994427" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1529922" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antiplatelet and antithrombotic effects of organic nitrates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8198030" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11104737" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8017267" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Phenomenon of nitrate tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8901678" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : In vivo nitrate tolerance is not associated with reduced bioconversion of nitroglycerin to nitric oxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854041" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426022" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1529932" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9857880" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2562937" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11127478" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nitroglycerin rebound associated with vascular, rather than platelet, hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11216970" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7829787" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: potential role of rebound ischemia during the nitrate-free period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7850984" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7867175" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8093132" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11535566" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11923046" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7594088" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9355892" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9581727" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Randomized, double-blind, placebo-controlled study of the preventive effect of supplemental oral vitamin C on attenuation of development of nitrate tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521337" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Randomized, double-blind, placebo-controlled study of ascorbate on the preventive effect of nitrate tolerance in patients with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9809925" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9809926" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1901528" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prevention of nitrate tolerance with angiotension converting enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2118301" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817475" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Usefulness of losartan, captopril, and furosemide in preventing nitrate tolerance and improving control of unstable angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640997" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of diuretic therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/414612" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effects of long-term oral administration of isosorbide dinitrate on the antianginal response to nitroglycerin. Absence of nitrate cross-tolerance and self-tolerance shown by exercise testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10908246" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Delay in calling for help during myocardial infarction: reasons for the delay and subsequent pattern of accessing care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5073659" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Components of delay in the pre-hospital phase of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3079881" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Ineffectiveness of sublingual nitroglycerin in patients with dry mucous membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3136853" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Patients' knowledge of sublingual glyceryl trinitrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21412208" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : NitroMist nitroglycerin spray for angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7058754" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3574424" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of intervals between doses on the development of tolerance to isosorbide dinitrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2212374" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256699" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576678" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Nitrate therapy: new aspects concerning molecular action and tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24071762" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: a 12-week, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
